Clinical Trial Update: Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib hydrochloride with radiation therapy in various Stage III-IV squamous cell carcinomas of the head and neck; study terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip and Oral Cavity
• Squamous Cell Carcinoma of the Nasopharynx
• Squamous Cell Carcinoma of the Oropharynx
• Verrucous Carcinoma of the Larynx
• Verrucous Carcinoma of the Oral Cavity

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx | Phase 2 | Status: TERMINATED | Results posted: 2020-05-12